Silo Pharma (SILO) Stock Soars 47% After Europe Greenlights PTSD Patent

TLDR

• Silo Pharma surged 47.55% in after-hours trading Monday to $0.52
• The European Patent Office issued a Rule 71(3) communication signaling intent to grant a patent for its PTSD prevention therapy
• The patent covers methods using serotonin 4 (5-HT4) receptor agonists to prevent stress-induced fear and depressive behavior
• The patent is licensed exclusively from Columbia University and is expected to cover major European markets
• SILO has a market cap of roughly $4.98 million and remains well below its 52-week high of $1.18

💥 Find the Next KnockoutStock! Get live prices, charts, and KO Scores from KnockoutStocks.com, the data-driven platform ranking every stock by quality and breakout potential.

Silo Pharma got a jolt on Monday when the European Patent Office (EPO) issued a Rule 71(3) communication — essentially a formal notice of intent to grant a patent — covering a novel preventative therapy for PTSD.

Silo Pharma, Inc., SILO

The patent application, titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,” targets the serotonin 4 (5-HT4) receptor pathway. The approach focuses on preventing stress-induced fear and depressive-like behavior before it starts, rather than treating symptoms after the fact.

The patent is exclusively licensed from Columbia University. Silo Pharma is now evaluating Unitary Patent protection and national validations across Europe to expand its geographic coverage.

CEO Eric Weisblum called it a “high-value milestone” that strengthens the company’s global intellectual property position.

What the Patent Covers

The allowed claims specifically cover methods of preventing stress-induced fear, depressive-like behavior, and related affective disorders using selected 5-HT4 receptor agonists.

This is a different angle from most PTSD treatments, which target symptoms after onset. Silo’s approach is aimed at building stress resilience ahead of time.

The patent directly supports SPC-15, the company’s lead PTSD program. Silo’s broader pipeline also includes SP-26 for fibromyalgia and chronic pain, along with preclinical assets targeting Alzheimer’s disease.

Where the Stock Stands

SILO closed Monday’s regular session at $0.36 before spiking to $0.52 in after-hours trading — a move of 47.55%.

The stock’s 52-week range tells the wider story: it hit a high of $1.18 and a low of $0.22 over the past year. That’s a lot of ground covered for a company with a market cap of just under $5 million.

Benzinga’s stock rankings show SILO carrying a negative price trend across all time frames heading into Monday’s news.

The after-hours jump puts the stock back above $0.50 for the first time in recent trading, though it remains a fraction of its 52-week peak.

The EPO grant, once formally issued, is expected to protect Silo’s PTSD therapy across major European markets.

Considering a new stock? You may want to see what’s on our watchlist first.

Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.

✨ Limited Time Offer

Get 3 Free Stock Ebooks

            Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
        

        

            *                       
                    **Top 10 AI Stocks** - Leading AI companies
                
            *                       
                    **Top 10 Crypto Stocks** - Blockchain leaders
                
            *                       
                    **Top 10 Tech Stocks** - Tech giants
                
        

        

            
                📥 Get Your Free Ebooks